Non-Regulatory
March 13, 2018
Affibody Announces First Dosing in a Phase I Trial of ABY-039 for Autoimmune Diseases
Affibody Medical Investor Relations
Non-Regulatory
March 13, 2018
Affibody Announces First Dosing in a Phase I Trial of ABY-039 for Autoimmune Diseases